PXR, CAR and drug metabolism

Timothy M Willson1, Steven A Kliewer

  • 1GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, North Carolina 27709, USA. tmw20653@gsk.com

Insights

The pregnane X receptor (PXR) and constitutive androstane receptor (CAR) regulate drug metabolism and can cause interactions. Understanding their roles as sensors aids toxicological screening in drug discovery.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Toxicology

Background:

  • Drug metabolism involves mechanisms protecting against harmful chemicals, which can lead to adverse drug-drug interactions.
  • Orphan nuclear receptors, pregnane X receptor (PXR) and constitutive androstane receptor (CAR), are key regulators of drug metabolism.
  • These receptors link exposure to foreign compounds (xenobiotics) with metabolic processes.

Purpose of the Study:

  • To examine the roles of PXR and CAR as sensors of xenobiotics.
  • To discuss the application of PXR and CAR knowledge in toxicological screening for drug discovery.

Main Methods:

  • Review of existing literature on PXR and CAR.
  • Analysis of the regulatory functions of PXR and CAR in cytochrome P450 expression.
  • Exploration of PXR and CAR involvement in xenobiotic metabolism and drug interactions.

Main Results:

  • PXR and CAR are identified as critical transcriptional regulators of cytochrome P450 enzymes.
  • These receptors play a central role in mediating the body's response to xenobiotic exposure.
  • Dysregulation of PXR and CAR can contribute to adverse drug-drug interactions.

Conclusions:

  • PXR and CAR function as crucial sensors for xenobiotics, influencing drug metabolism.
  • Knowledge of PXR and CAR mechanisms is valuable for improving toxicological screening in drug development.
  • Targeting PXR and CAR pathways may offer strategies to mitigate adverse drug reactions.

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs01:21

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in determining the metabolic...